Efruxifermin

Cat. No.:	HY-P99930
CAS No.:	2375240-92-7
Target:	FGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis[1].
IC_{50} & Target	FGF21
In Vivo	Efruxifermin (0-100 mg/kg, SC, Once weekly, for 4 or 26 weeks) reduces body weight gain of Sprague Dawley rats in a dose-dependent manner[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male and female Sprague Dawley rats[1]
Dosage:	0, 1, 10, 30, 100 mg/kg
Administration:	Subcutaneous injection, Once weekly, for 4 or 26 weeks
Result:	Significantly reduced body weight gain after 4 and 26 weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged.

REFERENCES

[1]. Tillman EJ, et al. Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. Br J Pharmacol. 2022 Apr;179(7):1384-1394.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA